Aller au contenu

Publications scientifiques

  • article Kerdiles O, Oye Mintsa Mi-Mba MF, Coulombe K, Tremblay C and Émond V, Saint-Pierre M, Rouxel C, Berthiaume L, Julien P, Cicchetti F, Calon F

    Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson’s disease

    Neural Regen Res 20 (2), 2025.

    DOI PUBMED
  • article Alpaugh M, Lantero-Rodriguez J, Benedet AL, Manseau U, Boutin M, Maiuri M, Denis HL, Masnata M, Fazal SV, Chouinard S, Rosa-Neto P, Barker RA, Blennow K, Zetterberg H, Labib R, Cicchetti F

    Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severity

    J Neurol 272 (3), 2025.

    DOI PUBMED
  • article Denis HL, de Rus Jacquet A, Alpaugh M, Panisset M, Barker RA, Boilard É and Cicchetti F

    Erythrocyte-derived extracellular vesicles transcytose across the blood-brain barrier to induce Parkinson’s disease-like neurodegeneration

    Fluids Barriers CNS 22 (1), 2025.

    DOI PUBMED
  • article Lemarchant S, Engelhardt B, Cicchetti F, Bix GJ, Janus A, Godfrin Y, Blasco H, Campbell M, de Rus Jacquet A

    Restoring brain barriers: an innovative approach for treating neurological disorders

    Fluids Barriers CNS 22 (1), 2025.

    DOI PUBMED
  • article Hadjas LC, Kollman GJ, Linderhof L, Xia M, Mansur S, Saint-Pierre M, Lim BK, Lee EB, Cicchetti F, Awatramani R, Hollon NG, Hnasko TS

    Parkinson’s Disease-vulnerable and -resilient dopamine neurons display opposite responses to excitatory input

    bioRxiv 2025.

    DOI PUBMED
  • article Lepinay E, Saint-Pierre M, Teixeira M, Snapyan M, Oueslati A, Parent M, Alpaugh M, Cicchetti F

    The impact of tau deletion on Huntingtons disease: an in vivo perspective

    Mol Ther 2025.

    DOI PUBMED
  • article Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, Balazs K, Oueslati A, Parth M, Salhat N, Siddu A, Smrzka O, Cicchetti F, Straffler G, Hayden MR, Southwell AL

    Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease

    Neurobiol Dis 190 2024.

    DOI PUBMED
  • article Tan K, Alpaugh M, Ashton NJ, Chouinard S, Barker RA, Blennow K, Zetterberg H, Cicchetti F, Benedet AL

    Plasma GFAP and its association with disease severity in Huntington’s disease

    J Neurol 271 (4), 2024.

    DOI PUBMED
  • article Salem S, Kilgore MD, Anwer M, Maxan A, Child D, Bird TD, Keene CD, Cicchetti F, Latimer C

    Evidence of mutant huntingtin and tau-related pathology within neuronal grafts in Huntington’s disease cases

    Neurobiol Dis 198 2024.

    DOI PUBMED
  • article Cardim-Pires TR, de Rus Jacquet A, Cicchetti F

    Healthy blood, healthy brain: a window into understanding and treating neurodegenerative diseases

    J Neurol 271 (6), 2024.

    DOI PUBMED
  • article Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, Balazs K, Oueslati A, Parth M, Salhat N, Siddu A, Smrzka O, Cicchetti F, Staffler G, Hayden MR, Southwell AL

    Corrigendum to « Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease » [Neurobiology of Disease, 2024 Jan:190:106376]

    Neurobiol Dis 193 2024.

    DOI PUBMED
  • article Salem S, Alpaugh M, Saint-Pierre M, Alves-Martins-Borba FN, Cerquera-Cleves C, Lemieux M, Ngonza-Nito SB, De Koninck P, Melki R, Cicchetti F

    Treatment with Tau fibrils impact Huntington’s disease-related phenotypes in cell and mouse models

    Neurobiol Dis 202 2024.

    DOI PUBMED